Knight Therapeutics (TSE:GUD) Sets New 1-Year High – Still a Buy?

Knight Therapeutics Inc. (TSE:GUD)’s stock price reached a new 52-week high on Tuesday. The company traded as high as C$10.41 and last traded at C$10.41, with a volume of 22311 shares. The stock had previously closed at C$10.27.

Knight Therapeutics Stock Performance

The company has a debt-to-equity ratio of 4.29, a quick ratio of 1.79 and a current ratio of 2.28. The company has a market capitalization of C$1.04 billion, a P/E ratio of 70.60, a PEG ratio of -1,013.50 and a beta of -0.29. The company’s fifty day simple moving average is C$9.82 and its 200-day simple moving average is C$8.87.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings results on Thursday, August 6th. The company reported C($0.03) EPS for the quarter. Knight Therapeutics had a net margin of 2.72% and a return on equity of 1.91%. The business had revenue of C$143.97 million during the quarter. Research analysts predict that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.